TICKERNERD
Menu
CRLCRLHealthcare · Diagnostics & Research

CRL Stock Forecast: Charles River Laboratories International, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$302
+1.00% on the day

The 18 Wall Street analysts covering Charles River Laboratories International, Inc. hold a median 12-month price target of $325 — +7.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 14 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$14.4B
Ticker Nerd rank
84 / 100
Median analyst target
$325
Analysts covering
18
Revenue$1.0B−2.7% y/y
Operating income$119.9M
Net income−$760K
Free cash flow$148.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.6%
1M
+10.6%
YTD
+51.4%
1Y
+77.5%
From 52W high
−2.8%
From 52W low
+101.4%
$150
$311
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Charles River Laboratories International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
84 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
90
Accruals
90
Revisions
82
Value
65
Growth
64
Issuance
61
Quality
57
Volatility
49
Size
12

Momentum (90): The shares have been drifting up relative to others.

Volatility (49): The share price moves around a lot.

Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250$300$350Jan 26Apr 26Jul 26Oct 26CRLHigh $357Median $325Low $145

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
15 Buy2 Hold1 Sell
Low $145Median $325High $357

The green dot is the last close — the median target sits +7.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 14 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
30 Sept 2026UBSReinstatesBuy$357
28 Sept 2026JefferiesMaintainsBuy$305 → $340
25 Sept 2026BairdMaintainsOutperform$291 → $334
25 Sept 2026BarclaysMaintainsOverweight$300 → $330
25 Sept 2026Deutsche BankMaintainsBuy$300 → $320
25 Sept 2026Evercore ISI GroupMaintainsOutperform$320 → $330
25 Sept 2026MizuhoMaintainsNeutral$264 → $295
25 Sept 2026RBC CapitalMaintainsOutperform$282 → $322
25 Sept 2026TD CowenMaintainsBuy$300 → $325
11 Sept 2026Evercore ISI GroupMaintainsOutperform—
11 Sept 2026Evercore ISI GroupMaintainsOutperform$300 → $320
10 Aug 2026TD CowenMaintainsBuy$235 → $300
10 Aug 2026TD CowenMaintainsBuy—
7 Aug 2026Morgan StanleyMaintainsOverweight—
7 Aug 2026Morgan StanleyMaintainsOverweight$260 → $300
6 Aug 2026Evercore ISI GroupMaintainsOutperform$260 → $300
6 Aug 2026Evercore ISI GroupMaintainsOutperform—
6 Aug 2026JP MorganUpgradeOverweight—
6 Aug 2026JP MorganUpgradeOverweight$180 → $310
6 Aug 2026RBC CapitalMaintainsOutperform$215 → $282

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CRL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Charles River Laboratories International, Inc. returned +77.5% against +17.5% for the S&P 500, dividends included.

CRL vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26CRLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CRL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.4%
Analysts raising
4
Analysts cutting
1
Fundamentals

Charles River Laboratories International, Inc. (CRL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
681.3×

Cheaper than 1% of US stocks

Price / sales
3.6×

Cheaper than 33% of US stocks

Price / book
5.0×

Cheaper than 19% of US stocks

EV / EBITDA
20.4×

Cheaper than 15% of US stocks

Growth & margins
Revenue growth (YoY)
−2.7%

Higher than 23% of US stocks

Earnings growth (YoY)
−2.7%

Higher than 33% of US stocks

Gross margin
36.2%

Higher than 44% of US stocks

Operating margin
15.1%

Higher than 73% of US stocks

Net margin
−6.0%

Higher than 23% of US stocks

Returns & dividend
Return on equity
−7.5%

Higher than 38% of US stocks

Return on assets
4.1%

Higher than 72% of US stocks

Dividend yield
0.4%

Higher than 65% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Charles River Laboratories International, Inc. (CRL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Charles River Laboratories International, Inc. has a market value of $14.4B and an enterprise value of $17.3B.

  • Revenue in the twelve months to 30 June 2026: $4.0B. The latest quarter shrank 2.7% year on year.

  • Net income over the same four quarters: −$236.3M, a −5.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−4.85.

  • Free cash flow in the twelve months to 30 June 2026: $370.6M, after $211.5M of capital spending.

  • Charles River Laboratories International, Inc. spent $324.1M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 47.7M.

  • Trailing P/E: 681.3×; forward P/E: 23.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.40%, paying out 0% of earnings.

  • Charles River Laboratories International, Inc. employs 18,300 people — $219K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Oct 2026

Data provided by Twelve Data

Peers

CRL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
CRLCharles River Laboratories International, Inc.$14.4B
84
RVTYRevvity, Inc.$17.0B
95
ICLRICON plc$12.9B
72
MEDPMedpace Holdings, Inc.$17.6B
98
GHGuardant Health, Inc.$21.1B
52
QGENQIAGEN NV$9.4B
68
DGXQuest Diagnostics, Inc.$26.0B
93

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Charles River Laboratories International, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRL news & analysis

Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development

Business Wire · 13 Oct 2026positive

Charles River Laboratories and Magellan Stem Cells announced a collaboration to support the development and clinical advancement of Magellan’s stem cell-based therapies and regenerative medicine solutions. The collaboration will draw on Charles River’s expertise in biologics quality control and cGMP viral services.

Why it matters — The partnership highlights Charles River’s role in supporting development and clinical advancement of cell therapies and regenerative medicine.

PGNY or CRL: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 7 Oct 2026neutral

Zacks Investment Research compares Progyny and Charles River Laboratories as potential value stocks, asking which may be the better option for investors seeking undervalued stocks.

Why it matters — The item directly compares CRL with Progyny in the context of value investing.

Charles River Gains 75.8% in a Year: What's Driving the Rally?

Zacks Investment Research · 7 Oct 2026positive

Charles River Laboratories shares rose 75.8% over the past year, with the excerpt citing improving RMS trends, expansion of AI-enabled testing, and cash flow supporting buybacks and investment.

Why it matters — These cited operating trends and uses of cash provide context for the factors associated with CRL’s share-price rise.

Charles River and Autolomous Partner to Transform Laboratory Execution Systems

Business Wire · 6 Oct 2026positive

Charles River Laboratories and Autolomous announced Apollo Orchestrate, a capability within Charles River’s Apollo platform that connects and digitizes laboratory execution using Autolomous’s autoloMATE digital Laboratory Execution System. The launch was described as progress on Charles River’s commitment to modernize and digitize laboratory workflows.

Why it matters — CRL watchers may note the partnership’s addition of a digital laboratory execution capability to the Apollo platform.

FAQ

Frequently asked questions about CRL stock

What is the CRL stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Charles River Laboratories International, Inc. have a median 12-month price target of $325, with estimates ranging from $145 to $357. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRL stock a buy right now?

Of the 18 analysts covering Charles River Laboratories International, Inc., 15 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Charles River Laboratories International, Inc. 84 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRL?

As at 14 Oct 2026, Charles River Laboratories International, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (90 of 100).

Will CRL stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +7.6% from the last close, and Ticker Nerd's factor model ranks Charles River Laboratories International, Inc. 84 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRL stock forecast for 2030?

No analyst covering Charles River Laboratories International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $145 to $357 over the next 12 months.

How has CRL stock performed over the past year?

Charles River Laboratories International, Inc. returned +77.5% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Charles River Laboratories International, Inc. do?

Charles River Laboratories International, Inc. is a global drug development services company that supports pharmaceutical, biotechnology, and medical device organizations across the research and preclinical stages.

What is the latest news on CRL?

The most recent item we track (Business Wire, 13 Oct 2026): "Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development". Charles River Laboratories and Magellan Stem Cells announced a collaboration to support the development and clinical advancement of Magellan’s stem cell-based therapies and regenerative medicine solutions. The collaboration will draw on Charles River’s expertise in biologics quality control and cGMP viral services.

Company

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. is a global drug development services company that supports pharmaceutical, biotechnology, and medical device organizations across the research and preclinical stages. Charles River Laboratories provides research models, discovery services, non-clinical safety assessment, and manufacturing-related testing solutions that help clients evaluate new therapies and products before clinical use. Its business spans three main segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. The company also offers specialized support for biologics, microbial testing, endotoxin testing, and cell-based research, serving customers in life sciences, academia, and government research. Headquartered in Wilmington, Massachusetts, Charles River Laboratories plays a key role in the outsourced research and development ecosystem by supplying the tools, services, and scientific expertise used to advance drug discovery and product safety worldwide.

CEO Ms. Birgit Girshick · 18,300 employees · United States · https://www.criver.com